Table 1 The baseline demographics and clinical characteristics between 2021 and 2022

Demographics

 Gender (Male/Female)

57/38

65/37

0.591

 Age (Mean), years

65

67

0.45

 BMI (Mean)

24

23

0.63

 DBP(M ± SD), mmHg

76.22 ± 9.26

75.75 ± 17.74

0.09

DVT attributes

 Type of DVT

 Unilateral distal

 Unilateral proximal

 Bilateral distal

 Bilateral proximal

36(37.9%)

26(27.4%)

23(24.2%)

10(10.5%)

43(42.2%)

25(24.5%)

25(24.5%)

9(8.8%)

0.528

 Risk grade of DVT

 0 grade

 1 grade

 2 grade

4(4.2%)

57(60%)

34(35.8%)

3(2.9%)

53(52%)

46(45.1%)

0.398

 PE

 None

 Periphery

 Central

59(62.1%)

7(7.4%)

29(30.5%)

60(58.8%)

8(7.8%)

34(33.4%)

0.894

Median follow up (Range), days

124 (96–421)

116.5 (91–446)

< 0.0001

 Hemorrhage events

 None

 Minor

 Major

79

15

1

91

10

1

0.199

 Therapeutic outcomes

 Stable condition

 Remission

 Aggravation

23(24.2%)

53(55.8%)

19(20%)

33(32.3%)

34(33.3%)

35(34.3%)

0.005

Clinical characteristics

 Diagnosis

0.319

  Advanced lung cancer (SCC/adenocarcinoma/SCLC)

10/33/4

10/34/5

  Postoperative

10

11

  Benign lung diseases (None/Interstitial lung disease/Tuberculosis/ COPD/Pneumonia/Bronchiectasis/PAH)

2/4/8/3/13/6/2

7/5/5/10/5/6/4

 Ongoing treatment

0.197

  Antitumor

47(49.5%)

57(55.9%)

  HREZ

  anti-infection

  hemostasis

  None

8(8.4%)

23(24.2%)

4(4.2%)

13(13.7%)

5(4.9%)

14(13.7%)

5(4.9%)

21(20.6%)

 Time from active ongoing treatment to DVT confirmed, months (< 6/6–12/>12)

83/9/3

83/7/12

0.067

 COVID-19(None/Previously diagnosed within 6 months)

88/7

43/59

< 0.001

Relevant blood biochemistry tests

 RBC (< 4.3*10¹²/L / >4.3*10¹²/L)

56/39

60/42

1

 WBC (< 9.5*10¹²/L / >9.5*10¹²/L)

72/23

79/23

0.867

 PLT (< 125*10⁹/L / >125*10⁹/L)

8/87

22/80

0.016

 ALT (< 49IU/L / >49IU/L)

81/14

92/10

0.29

 CRE (< 97umol/L / >97umol/L)

91/4

93/9

0.2

 D-dimer level ( Decreased / Increased )

66/29

67/35

0.571

 PT (< 11s / >11s)

18/77

27/75

0.237